Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 13/20 | 0.38 |
| ▸ | TP53 | P04637 | 7/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22004313 | 0.86 | ACLY (0.47) | ACLYCYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL22004373 | 0.86 | ACLY (0.52) | ACLYPIK3CA | |
| SCHEMBL22004122 | 0.82 | ACLY (0.46) | ACLYMAPTTHRB | |
| SCHEMBL22004330 | 0.82 | ACLY (0.50) | ACLYTP53MAPTTHRB | |
| SCHEMBL22005071 | 0.81 | ACLY (0.47) | ACLYCYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL22004333 | 0.81 | ACLY (0.53) | ACLYMDM2TP53CYP1A2CYP3A4 | |
| SCHEMBL22004395 | 0.78 | KCNH2 (0.45) | ACLYMAPTTHRB | |
| SCHEMBL22003798 | 0.77 | ACLY (0.44) | ACLYMAPTTHRB | |
| SCHEMBL22004326 | 0.77 | ACLY (0.47) | ACLYMAPTTHRB | |
| SCHEMBL22003806 | 0.76 | HTT (0.50) | ACLYCYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885MDM2 3568/4885TP53 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.